FDA · United States
alogliptin benzoate — FDA regulatory status
alogliptin benzoate (VIPIDIA) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.
Status snapshot
- Status
- FDA approved
- Brand
- VIPIDIA
- Originator
- Takeda
- Mechanism
- Dipeptidyl peptidase IV inhibitor
- Target
- Dipeptidyl peptidase 4
- Structured fields
- 8
Sponsor / originator context: Takeda. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.
Pharmacology context used for competitive intelligence: Dipeptidyl peptidase IV inhibitor. Target: Dipeptidyl peptidase 4. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — FDA: approved.
Linked evidence on this spoke: 16 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| FDA | United States | approved | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Alogliptin | Phase 3 | Takeda | NCT01263496, NCT00328627 |
| Alogliptin | Phase 3 | Takeda | NCT01521962, NCT00306384 |
| Alogliptin Benzoate | Phase 3 | Takeda | NCT02856113 |
| Alogliptin and glimepiride | Phase 3 | Takeda | NCT01318083, NCT01318135 |
| Alogliptin and glyburide | Phase 3 | Takeda | NCT00286468 |
| Alogliptin and insulin | Phase 3 | Takeda | NCT00286429 |
| Alogliptin and metformin | Phase 3 | Takeda | NCT00286442 |
| Alogliptin and metformin | Phase 3 | Takeda | NCT01318109 |
| Alogliptin and pioglitazone | Phase 3 | Takeda | NCT01318070, NCT01318122 |
| Alogliptin and pioglitazone | Phase 3 | Takeda | NCT00286494, NCT00655863 |
| Alogliptin and voglibose | Phase 3 | Takeda | NCT01263483, NCT01263509 |
| Alogliptin | Phase 1 | Takeda | NCT02508168, NCT03501277 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12421188 | Heterocyclic compound and use thereof | US |
| 12415782 | Heterocyclic compound and use thereof | US |
| 12409210 | CNS delivery of therapeutic agents | US |
| 12391760 | Method of treating primary sclerosing cholangitis | US |
| 12391765 | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies | US |
| 12383587 | AAV triple-plasmid system | US |
| 12384770 | Heterocyclic compound | US |
| 12378256 | Heterocyclic compound | US |
| 12358879 | Heterocyclic compound | US |
| 12337020 | Bacteriophage compositions | US |
| 12319940 | Methods for purification of arylsulfatase A | US |
| 12290531 | Compositions targeting BCMA and methods of use thereof | US |
Related hubs
FAQ
What is the FDA approval status of alogliptin benzoate?
alogliptin benzoate currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get alogliptin benzoate regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to alogliptin benzoate?
This spoke lists 16 published programs associated with alogliptin benzoate in our pipeline index.